QIAGEN Buys CTC Technology

The acquired technology uses immunomagnetic cell enrichment and then RT-PCR for mRNA purification. Part of AdnaGen’s portfolio is already recommended for use with QIAGEN’s automation systems and kits.

Germantown, MD and Hilden, Germany 3/16/15; Cambridge, MA 3/16/15—QIAGEN has acquired certain technology and other assets from AdnaGen, a subsidiary of Alere, including the CE-IVD marked products AdnaTest Breast Cancer and AdnaTest Prostate Cancer. Terms were not disclosed. The technology enables enrichment and molecular analysis of circulating tumor cells from blood samples. QIAGEN will exclusively license the technology to Tokai Pharmaceuticals. QIAGEN and Tokai will codevelop and commercialize a companion diagnostic to guide treatment of prostate cancer.

< | >